ALK Laboratorierne AS
http://medizin.li
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ALK Laboratorierne AS
Stallergenes' Mite Allergy Results An Early Leaving Present For Retiring CEO
Positive Phase III data with its sublingual house dust allergy tablet heralds a likely increase in competition in the US allergy sector in the years to come and also provide an early leaving present for the company's retiring CEO.
Pipeline Watch: Phase III Starts With Atezolizumab, CNTX-4975 And WTX101
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
EOC Gears To Evolve Into Integrated Oncology Company
Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.
Pipeline Watch: Phase III Progress With Esaxerenone, Lusutrombopag
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Company Information
- Industry
- In Vitro Diagnostics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice